Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
about
Immunotherapy for cancer in the central nervous system: Current and future directionsBacteria in Cancer Therapy: Renaissance of an Old ConceptSpontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatmentCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateTumor immunotherapy: lessons from autoimmunityIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsSalmonella as an innovative therapeutic antitumor agent.Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Why has active immunotherapy not worked in lung cancer?T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyPD-1 blockade enhances the vaccination-induced immune response in gliomaSolid tumors provide niche-specific conditions that lead to preferential growth of Salmonella.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.Methods for the development of tumor-targeting bacteria.Targeting cancer-specific mutations by T cell receptor gene therapy.A perspective on the impact of radiation therapy on the immune rheostat.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Antimelanoma effect of Salmonella Typhimurium integration host factor mutant in murine model.The Boosting Potential of Bacteria in Cancer Immunotherapy.Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome.Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Cancer Orthotopic Mouse Model.An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.Salmonella Typhimurium increases functional PD-L1 synergistically with IFNγ in intestinal epithelial cells via Salmonella Pathogenicity Island-2.Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.T-Cell Epitope Discovery for Therapeutic Cancer Vaccines.Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.Current Strategies to Enhance Anti-Tumour Immunity.Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
P2860
Q26750765-25DDDBE5-2F0D-4DD1-B2F6-675A1D998DF7Q26751222-FA114E0C-6523-4B36-A430-4B6963EB7B29Q26774238-F79E5618-9463-4E55-9A95-A1A057F83DF6Q26782573-4F345218-C922-499D-A6B8-EAEC402B1D81Q26866179-2295B23D-C413-43DA-8D2C-68DB2646E68DQ28072532-49596FED-C2F0-40F8-8522-417CB0019D85Q34158653-80C91A6F-B427-48C1-AF65-7F8D25F65261Q36173622-77055DBF-0C1F-437B-8FB9-D85B14523850Q36207901-512514E2-6C01-4461-88D0-AFC99213B49BQ36436758-D1C74187-0F70-4FBE-A595-F5220721AA2EQ37109193-048589D1-1978-4E6C-904A-0514E5F1BB3AQ37376492-37ED6D48-3238-4C12-9020-A2D1E951F5DEQ37529144-6AFAC79A-2D41-4A31-870B-DF894AFA8AC0Q37582737-6E694592-89E4-47C5-BDC0-6269B3C42D70Q38221907-E53B6B38-84B0-4E1E-8828-4254952E4A58Q38366556-36A03A50-515F-4A20-8CA9-DF70CEB2DEEBQ38679488-782DDED0-5505-47F9-AAA1-0ACD9E531BE1Q38769021-98AECCEF-9745-4FB6-9F4D-C22D9AE1E849Q38850160-85F1F14B-B14E-44F1-8ED4-A446CC2A6631Q39352759-42AA1EB2-FE47-481F-A3C0-DC86A973CE84Q39546521-F3DE37A7-3897-4A33-93FD-626A94ACAB53Q40108146-42FC3592-1715-40DB-A068-EB48B2FF7B10Q40163572-3C715D42-E90B-4E96-9E67-1E9C1A94F088Q46115870-97BC5566-8F00-409C-AACA-12CCA72FABA6Q47161735-16D4A5A6-2E16-46E8-B02F-F201E79D3D84Q49923839-D2B7765A-6DCF-4D12-8BCA-1F701CD70B94Q50333648-D7AA8BDC-3970-47D5-8F33-5696F57C0A35Q50861629-853EE3DB-EDFB-4C6E-9838-5535A587D0B7Q50957786-92DFA4EE-994D-43BC-9EAE-813E4C260FF0Q52344613-A9ED0F9C-7B3C-45BC-A665-50D7A9AA9023Q52763519-78AFCE71-C63F-4956-8EC9-7CE170B3E965Q58740200-C7A8AC63-3B18-467A-9661-CB7F10DDDC19
P2860
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antigen-specific bacterial vac ...... eject long-established cancer.
@en
Antigen-specific bacterial vac ...... eject long-established cancer.
@nl
type
label
Antigen-specific bacterial vac ...... eject long-established cancer.
@en
Antigen-specific bacterial vac ...... eject long-established cancer.
@nl
prefLabel
Antigen-specific bacterial vac ...... eject long-established cancer.
@en
Antigen-specific bacterial vac ...... eject long-established cancer.
@nl
P2093
P2860
P1476
Antigen-specific bacterial vac ...... reject long-established cancer
@en
P2093
Ainhoa Arina
Boris Engels
Byron Burnette
Christian Idel
David C Binder
Donald A Rowley
Hans Schreiber
James M Slauch
P2860
P304
P356
10.1158/2326-6066.CIR-13-0058
P577
2013-08-01T00:00:00Z